1-3 of 3
Vito Palombella, PhD
Close
Sort by
Journal Articles

Duvelisib (IPI-145) Inhibits Malignant B-Cell Proliferation and Disrupts Signaling from the Tumor Microenvironment through Mechanisms That Are Dependent on PI3K-δ and PI3K-γ

Marisa Peluso, MS, Kerrie Faia, MS, David Winkler, PhD, Nidhi Patel, MS, Erin Brophy, BS, Kerry White, BA, Mark Douglas, MS, Howard M. Stern, MD PhD, Vito Palombella, PhD, Karen McGovern, PhD, Jeffery L. Kutok, MD PhD
Journal: Blood
Blood (2014) 124 (21): 328.
https://doi.org/10.1182/blood.V124.21.328.328
Published: 2014
Journal Articles

Phase I Clinical Trial of IPI-504, a Novel, Water-Soluble Hsp90 Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM).

Sundar Jagannath, MD, David Siegel, MD, Paul Richardson, MD, Amitabha Mazumder, MD, Jens Sydor, PhD, Jill Goddard, John Walker, Jon Patterson, Emmanuel Normant, PhD, Jeffrey Tong, PhD, Vito Palombella, PhD, Ken Anderson, MD, Julian Adams, PhD, David Grayzel, MD
Journal: Blood
Blood (2005) 106 (11): 2560.
https://doi.org/10.1182/blood.V106.11.2560.2560
Published: 2005
Journal Articles

IPI-504: A Novel hsp90 Inhibitor with In Vitro and In Vivo Anti-Tumor Activity.

Constantine S. Mitsiades, MD, PhD, Nicholas Mitsiades, MD, PhD, Melissa Rooney, Joseph Negri, Corey C. Geer, MSc, Melissa Pink, Christine Pien, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Nikhil C. Munshi, MD, PhD, Paul G. Richardson, MD, John Barrett, PhD, Jeffrey K. Tong, PhD, David Grayzel, Vito Palombella, PhD, Julian Adams, PhD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2004) 104 (11): 2403.
https://doi.org/10.1182/blood.V104.11.2403.2403
Published: 2004